Mohamed El-Shahawy, MD
Nephrology · Los Angeles, CANPI 1760411151
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by AstraZeneca at 32.5% of the total. Reporting peaked in 2019 at $15,128 and has fallen 96.1% since, to $583 in 2025. Among nephrology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 133 payments — averaging $197.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$9K
- Bayer$6K
- CSL Behring$4K
- Alnylam Pharmaceuticals Inc.$3K
- Merck$2K
- UCB SA$787
- plus $3K from 14 others
Across 1,005 payments — averaging $4399.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$2M
- CSL Behring$459K
- Bayer$322K
- GSK$281K
- Akebia Therapeutics Inc$279K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$257K
- plus $861K from 15 others
What the payments were for
- Consulting fees$11,75045%
- Speaking & faculty fees$5362%
- Travel & lodging$9,66837%
- Food & beverage$4,09016%
- Education$2331%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 21 | $8,529 |
| Bayer | 12 | $6,091 |
| CSL Behring | 16 | $3,556 |
| Alnylam Pharmaceuticals Inc. | 9 | $2,501 |
| Merck | 16 | $2,231 |
| UCB SA | 6 | $787 |
| Pharmacosmos Therapeutics Inc. | 1 | $536 |
| Otsuka America Pharmaceutical, Inc. | 17 | $513 |
| Amgen | 12 | $295 |
| GSK | 8 | $278 |
| Apellis Pharmaceuticals, Inc. | 3 | $211 |
| Fresenius USA Marketing, Inc. | 2 | $179 |
| Baxter Healthcare | 3 | $171 |
| Novartis | 1 | $139 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $125 |
| Genentech USA, Inc. | 1 | $46 |
| Vifor Pharma, Inc. | 1 | $25 |
| Akebia Therapeutics Inc | 1 | $25 |
| Ardelyx, Inc. | 1 | $20 |
| Cleerly, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$8,017
- Non-Covered$5,651
- Monoferric$536
- BENLYSTA$123
- Parsabiv$119
- Kerendia$118
- Renal - PD$101
How this compares
$26,276 in reported general payments places this provider in the 90th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 17 | $74,991 |
| KerendiaFinerenone | 19 | $18,208 |
| OzempicSemaglutide | 14 | $17,916 |
| LokelmaSodium Zirconium Cyclosilicate | 11 | $15,072 |
| EliquisApixaban | 20 | $13,896 |
| ProcritEpoetin Alfa | 23 | $11,939 |
| VeltassaPatiromer Calcium Sorbitex | 19 | $11,753 |
| JardianceEmpagliflozin | 21 | $11,204 |
| Sevelamer Carbonate | 30 | $7,911 |
| Calcium Acetate | 51 | $4,260 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $4,245 |
| Clonidine | 30 | $3,841 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $3,015 |
| Midodrine Hcl | 13 | $1,612 |
| Alcohol Prep PadsAlcohol Antiseptic Pads | 22 | $1,234 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $179 | $74,99117 claims |
| BayerKerendia | $6,091 | $18,20819 claims |
| AstraZenecaLokelma | $8,529 | $15,07211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,341 nephrology providers in California.
Other nephrology in Los Angeles
- Anjay RastogiLos Angeles$2.2M
- Suphamai BunnapradistLos Angeles$498K
- Mohammad KamgarLos Angeles$497K
- Victor CarabelloLos Angeles$363K
- Tariq ShahLos Angeles$351K
- Susanne NicholasLos Angeles$146K
- Arishia GhaffariLos Angeles$142K
- Allen NissensonLos Angeles$101K
- Niloofar NobakhtLos Angeles$97K
- Farid ArmanLos Angeles$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.